Physician profile
Amresh Raina
NPI 1447450705
$4,439.68
in general payments reported to CMS, 2019-2025
15 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $154 · 2021: $82.83 · 2022: $3,192 · 2023: $378 · 2024: $137 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.69 |
| Education | $109.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,126.72 | 2022-2024 | Winrevair |
| Abbott Laboratories | $325.30 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Actelion Pharmaceuticals US, INC. | $318.49 | 2019-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $223.52 | 2020-2023 | |
| United Therapeutics Corporation | $80.95 | 2022-2024 | Orenitram, Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $67.25 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $63.94 | 2021 | |
| Pfizer INC. | $60.54 | 2020-2024 | |
| Vifor Pharma, INC. | $56.57 | 2019-2021 | |
| Sandoz INC. | $29.96 | 2025 | Treprostinil |
| Medtronic Vascular, INC. | $28.39 | 2019 | |
| Amgen INC. | $24.65 | 2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $18.63 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.77 | 2024 | Jardiance |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amresh Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.